Comparative Pharmacology
Head-to-head clinical analysis: AZACTAM IN PLASTIC CONTAINER versus AZTREONAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZACTAM IN PLASTIC CONTAINER versus AZTREONAM.
AZACTAM IN PLASTIC CONTAINER vs AZTREONAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aztreonam binds to penicillin-binding proteins (PBPs) of susceptible bacteria, inhibiting bacterial cell wall synthesis. It is a monobactam with activity against aerobic gram-negative bacteria.
Aztreonam is a monobactam antibacterial that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 3 (PBP3) of Gram-negative bacteria, leading to cell death.
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
1-2 g IV or IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
1.7-2.1 hours (normal renal function); prolonged to 4.2-6.0 hours in ESRD (CrCl <10 mL/min).
Clinical Note
moderateAztreonam + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aztreonam."
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; prolonged to 6-9 hours in end-stage renal disease (CrCl <10 mL/min).
Primarily renal (75-85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Renal: 60-70% unchanged via glomerular filtration and tubular secretion; nonrenal: 30-40% (hepatic metabolism to inactive metabolites and biliary excretion, with <1% fecal elimination).
Category C
Category C
Monobactam Antibiotic
Monobactam Antibiotic